Shots:

•  Basilea to conduct the P-I/II biomarker-driven clinical trial with its expected initiation in H1’2019 and Roche to provide atezolizumab for the trial
•  The focus of the agreement is for the onset of the trial assessing Basilea's derazantinib in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced (UC) and FGFR genomic defects
•  Derazantinib (BAL087- formerly ARQ 087) is a panFGFR kinase inhibitor- in-licensed from ArQule in Aprl- 2018 and has received ODD from the US and EU for intrahepatic cholangiocarcinoma (iCCA). Tecentriq (atezolizumab) is a mAb inhibiting PD-L1 while blocking its interaction with PD-1 and B7.1 receptors

   Ref:  Basilea | Image: Roche